PL3717011T3 - Sposób leczenia lub zapobiegania uszkodzeniu niedokrwienno- reperfuzyjnemu - Google Patents

Sposób leczenia lub zapobiegania uszkodzeniu niedokrwienno- reperfuzyjnemu

Info

Publication number
PL3717011T3
PL3717011T3 PL18883859.3T PL18883859T PL3717011T3 PL 3717011 T3 PL3717011 T3 PL 3717011T3 PL 18883859 T PL18883859 T PL 18883859T PL 3717011 T3 PL3717011 T3 PL 3717011T3
Authority
PL
Poland
Prior art keywords
treating
reperfusion injury
preventing ischemia
ischemia
preventing
Prior art date
Application number
PL18883859.3T
Other languages
English (en)
Inventor
Ingela VIKSTROM
Adriana BAZ MORELLI
Martin Pearse
Original Assignee
Csl Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017904822A external-priority patent/AU2017904822A0/en
Application filed by Csl Limited filed Critical Csl Limited
Publication of PL3717011T3 publication Critical patent/PL3717011T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
PL18883859.3T 2017-11-29 2018-11-29 Sposób leczenia lub zapobiegania uszkodzeniu niedokrwienno- reperfuzyjnemu PL3717011T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017904822A AU2017904822A0 (en) 2017-11-29 Method of treating or preventing ischemia-reperfusion injury
PCT/AU2018/051272 WO2019104385A1 (en) 2017-11-29 2018-11-29 Method of treating or preventing ischemia-reperfusion injury

Publications (1)

Publication Number Publication Date
PL3717011T3 true PL3717011T3 (pl) 2023-03-27

Family

ID=66663689

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18883859.3T PL3717011T3 (pl) 2017-11-29 2018-11-29 Sposób leczenia lub zapobiegania uszkodzeniu niedokrwienno- reperfuzyjnemu

Country Status (12)

Country Link
US (2) US20210179721A1 (pl)
EP (1) EP3717011B1 (pl)
JP (1) JP7465210B2 (pl)
KR (1) KR20200093562A (pl)
CN (1) CN111417406A (pl)
AU (1) AU2018377856A1 (pl)
BR (1) BR112020010514A2 (pl)
CA (1) CA3081770A1 (pl)
DK (1) DK3717011T3 (pl)
ES (1) ES2939461T3 (pl)
PL (1) PL3717011T3 (pl)
WO (1) WO2019104385A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021010920A2 (pt) * 2018-12-04 2021-08-31 CSL Innovation Pty Ltd Método de tratamento de condições neutrofílicas

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE66494B1 (en) 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
DK1087013T3 (da) 1992-08-21 2009-05-11 Univ Bruxelles Immunoglobuliner uden lette kæder
WO1994007921A1 (en) 1992-09-25 1994-04-14 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
ATE374248T1 (de) 1996-06-27 2007-10-15 Vlaams Interuniv Inst Biotech Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
DE69936946T2 (de) 1998-05-06 2008-05-15 Genentech, Inc., South San Francisco Reinigung von Antikörpern durch Ionenaustauschchromatographie
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
ATE448301T1 (de) 2000-09-08 2009-11-15 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
WO2002088171A2 (en) 2001-04-26 2002-11-07 Avidia Research Institute Combinatorial libraries of monomer domains
US7501494B2 (en) 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
EP1658095A4 (en) 2003-06-02 2006-06-14 Alexion Pharma Inc ANTI-CD3 ANTIBODY DESIMMUNISE
JP4871126B2 (ja) 2003-07-04 2012-02-08 アフィボディ・アーベー Ｈｅｒ２に対する結合親和性を有するポリペプチド
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
AU2004296376B2 (en) 2003-12-05 2010-03-04 Bristol-Myers Squibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
US7977071B2 (en) 2004-06-02 2011-07-12 Adalta Pty Ltd. Binding moieties based on shark ignar domains
US8911726B2 (en) 2004-09-22 2014-12-16 Kyowa Hakko Kirin Co., Ltd Stabilized human Igg4 antibodies
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
EP1924606A4 (en) 2005-08-25 2010-01-13 Repair Technologies Inc DEVICES, COMPOSITIONS AND METHODS FOR PROTECTING AND REPAIRING CELLS AND TISSUE
EP2526959B1 (en) * 2006-08-11 2017-08-02 CSL Limited Treatment of pulmonary disease conditions
US20080199426A1 (en) * 2007-01-11 2008-08-21 Sukhatme Vikas P Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
CL2008002782A1 (es) 2007-09-21 2009-07-31 Genentech Inc Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular.
CN106432503B (zh) 2008-12-19 2020-03-06 宏观基因有限公司 共价双抗体及其用途
US20120100140A1 (en) 2009-01-23 2012-04-26 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
ES2678144T3 (es) 2010-02-16 2018-08-09 Medimmune, Llc Composiciones relacionadas con SAH y métodos de uso
EP2367000A1 (en) 2010-03-04 2011-09-21 Charité Universitätsmedizin Berlin High throughput analysis of T-cell receptor repertoires
CA2826683A1 (en) 2011-02-15 2012-08-23 Medimmune, Llc Hsa-related compositions and methods of use
WO2012171057A1 (en) 2011-06-13 2012-12-20 Csl Limited Antibodies against g-csfr and uses thereof
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
US9050305B2 (en) 2012-03-29 2015-06-09 Chs Pharma, Inc. Treatment for ischemic stroke
GB2512156A (en) 2012-11-08 2014-09-24 Novozymes Biopharma Dk As Albumin variants
WO2014179657A1 (en) 2013-05-03 2014-11-06 Eleven Biotherapeutics, Inc. Albumin variants binding to fcrn
EP3063171B1 (en) 2013-11-01 2019-07-24 University Of Oslo Albumin variants and uses thereof
WO2016077878A1 (en) * 2014-11-17 2016-05-26 Csl Limited Method of treating or preventing stroke
RU2018139893A (ru) * 2016-04-21 2020-05-21 СиЭсЭл ЛИМИТЕД Способ лечения или предупреждения болезней печени

Also Published As

Publication number Publication date
CA3081770A1 (en) 2019-06-06
DK3717011T3 (da) 2023-01-09
BR112020010514A2 (pt) 2020-11-24
US20230279129A1 (en) 2023-09-07
KR20200093562A (ko) 2020-08-05
JP7465210B2 (ja) 2024-04-10
JP2021504382A (ja) 2021-02-15
CN111417406A (zh) 2020-07-14
EP3717011A1 (en) 2020-10-07
EP3717011B1 (en) 2022-12-07
WO2019104385A1 (en) 2019-06-06
EP3717011A4 (en) 2021-09-08
ES2939461T3 (es) 2023-04-24
US20210179721A1 (en) 2021-06-17
AU2018377856A1 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
GB2578539B (en) Compositions and methods for preventing or treating muscle conditions
IL262825A (en) Tetrahydropyridine and tetrahydropyrimidine substances, preparations containing them and their use for pain treatment
IL293712B1 (en) Methods for treating mild brain injury
ZA201903873B (en) Methods of treating cochlear synaptopathy
ZA202001880B (en) Compositions and methods for treating brain injury
GB2567616B (en) Treatment method
IL276577A (en) Methods for treating cardiac injury
ZA201908539B (en) Method of treatment of cancer
HK1256541A1 (zh) 用於處理皮膚的方法和組合物
GB201706406D0 (en) Method of treatment
GB2571601B (en) Treatment method
IL250658A0 (en) Methods for treating mild brain injury
GB201815588D0 (en) Method of treatment
ZA201806807B (en) Method for the treatment or prevention of osteoarthritis
HK1243635A1 (zh) 治療皮膚病況的組合物和方法
SG11202001806TA (en) Treatment method
IL270867A (en) Treatment method
GB201602802D0 (en) Method of treatment
ZA201802268B (en) Methods and compositions for preventing or treating cancer
PL3717011T3 (pl) Sposób leczenia lub zapobiegania uszkodzeniu niedokrwienno- reperfuzyjnemu
ZA201903931B (en) Method of treating meat
AU2017904822A0 (en) Method of treating or preventing ischemia-reperfusion injury
GB201720439D0 (en) Method of treatment
GB201718589D0 (en) Method of treatment
GB201709554D0 (en) Method of treatment